Amgen: The Quarter Where New Growth Engines Begin to Drown Out the Noise of Patent Expirations
The California-based biotech giant reported solid Q1 2026 results, with revenue up to $8.62bn, from $8.15bn a year ago, with net income reaching $1.82bn. Adjusted EPS came in at $5.15, beating market expectations of around $4.76 to $4.77 according to cited …